» Articles » PMID: 2428045

Isolation of a Human Erythrocyte Membrane Protein Capable of Inhibiting Expression of Homologous Complement Transmembrane Channels

Overview
Specialty Science
Date 1986 Sep 1
PMID 2428045
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Erythrocytes are poorly lysed by homologous complement, whereas they are readily lysed by heterologous complement. This phenomenon had been attributed to an interference by the cell surface with the action of complement components C8 and C9. To isolate the responsible membrane constituent, detergent-solubilized human erythrocyte (EH) membranes were subjected to affinity chromatography by using human C9-Sepharose. The isolated protein had a mass of 38 kDa and, incorporated into liposomes, was highly effective in inhibiting complement-mediated channel expression, including the C5b-8, membrane attack complex, and tubular polymer of C9 channels. Antibody produced to the 38-kDa protein caused a 20-fold increase in reactive lysis of EH by isolated C5b6, C7, C8, and C9. The antibody did not enhance C5b-7 uptake, but it affected C9 binding to the target cell membrane. Antibody to human decay-accelerating factor, used as a control, had no effect on reactive lysis of EH. Anti-38-kDa protein did not enhance the action on EH of C8 and C9 from other species, indicating that the action of this regulatory protein is species specific. It was therefore termed homologous restriction factor (HRF). Blood cells other than erythrocytes, such as polymorphonuclear leukocytes, also exhibited cell-surface HRF activity. In immunoblots of freshly isolated EH membranes, anti-38-kDa HRF detected primarily a 65-kDa protein, suggesting that the 38-kDa protein constitutes an active fragment of membrane HRF. Because of the specific binding reaction observed between HRF and C8 or C9, HRF was tested with anti-human C8 and anti-human C9. A limited immunochemical relationship of HRF to C8 and C9 could be established and solid-phase anti-C9 proved an efficient tool for the isolation of HRF from solubilized EH membranes.

Citing Articles

The Prospect of Biomimetic Immune Cell Membrane-Coated Nanomedicines for Treatment of Serious Bacterial Infections and Sepsis.

Hoffman A, Nizet V J Pharmacol Exp Ther. 2024; 389(3):289-300.

PMID: 38580449 PMC: 11125797. DOI: 10.1124/jpet.123.002095.


Application of Nanomaterials in the Prevention, Detection, and Treatment of Methicillin-Resistant (MRSA).

Hulme J Pharmaceutics. 2022; 14(4).

PMID: 35456638 PMC: 9030647. DOI: 10.3390/pharmaceutics14040805.


Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities.

Chiangjong W, Netsirisawan P, Hongeng S, Chutipongtanate S Front Med (Lausanne). 2022; 8:761362.

PMID: 35004730 PMC: 8739511. DOI: 10.3389/fmed.2021.761362.


Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.

Glassman P, Hood E, Ferguson L, Zhao Z, Siegel D, Mitragotri S Adv Drug Deliv Rev. 2021; 178:113992.

PMID: 34597748 PMC: 8556370. DOI: 10.1016/j.addr.2021.113992.


Extracellular Vesicles from Red Blood Cells and Their Evolving Roles in Health, Coagulopathy and Therapy.

Thangaraju K, Neerukonda S, Katneni U, Buehler P Int J Mol Sci. 2020; 22(1).

PMID: 33375718 PMC: 7796437. DOI: 10.3390/ijms22010153.


References
1.
Hoffmann E . Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action. Immunochemistry. 1969; 6(3):405-19. DOI: 10.1016/0019-2791(69)90297-3. View

2.
Zalman L, Brothers M, Chiu F, MULLER-EBERHARD H . Mechanism of cytotoxicity of human large granular lymphocytes: relationship of the cytotoxic lymphocyte protein to the ninth component (C9) of human complement. Proc Natl Acad Sci U S A. 1986; 83(14):5262-6. PMC: 323931. DOI: 10.1073/pnas.83.14.5262. View

3.
Klob W, MULLER-EBERHARD H . The membrane attack mechanism of complement: the three polypeptide chain structure of the eigth component (C8). J Exp Med. 1976; 143(5):1131-9. PMC: 2190193. DOI: 10.1084/jem.143.5.1131. View

4.
Yamamoto K . Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity. J Immunol. 1977; 119(4):1482-5. View

5.
Podack E, KOLB W, Esser A, MULLER-EBERHARD H . Structural similarities between C6 and C7 of human complement. J Immunol. 1979; 123(3):1071-7. View